[go: up one dir, main page]

ZA971820B - Improved vision through photodynamic therapy of the eye. - Google Patents

Improved vision through photodynamic therapy of the eye.

Info

Publication number
ZA971820B
ZA971820B ZA9701820A ZA971820A ZA971820B ZA 971820 B ZA971820 B ZA 971820B ZA 9701820 A ZA9701820 A ZA 9701820A ZA 971820 A ZA971820 A ZA 971820A ZA 971820 B ZA971820 B ZA 971820B
Authority
ZA
South Africa
Prior art keywords
eye
photodynamic therapy
improved vision
vision
improved
Prior art date
Application number
ZA9701820A
Other languages
English (en)
Inventor
H Andrew Strong
Julia Levy
Gustav Huber
Mario Fsadni
Original Assignee
Qlt Phototherapeutics Inc
Ciba Vision Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics Inc, Ciba Vision Ag filed Critical Qlt Phototherapeutics Inc
Publication of ZA971820B publication Critical patent/ZA971820B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
ZA9701820A 1996-03-11 1997-03-03 Improved vision through photodynamic therapy of the eye. ZA971820B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/613,420 US5756541A (en) 1996-03-11 1996-03-11 Vision through photodynamic therapy of the eye

Publications (1)

Publication Number Publication Date
ZA971820B true ZA971820B (en) 1997-10-10

Family

ID=24457246

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9701820A ZA971820B (en) 1996-03-11 1997-03-03 Improved vision through photodynamic therapy of the eye.

Country Status (21)

Country Link
US (6) US5756541A (xx)
EP (1) EP0894009B1 (xx)
JP (2) JP2000506173A (xx)
KR (1) KR100433507B1 (xx)
CN (1) CN1104908C (xx)
AR (2) AR004422A1 (xx)
AT (1) ATE301473T1 (xx)
CA (1) CA2248087C (xx)
CZ (1) CZ299301B6 (xx)
DE (1) DE69733943T2 (xx)
DK (1) DK0894009T3 (xx)
ES (1) ES2246505T3 (xx)
FI (1) FI981954A7 (xx)
HU (1) HU227978B1 (xx)
IL (4) IL126099A (xx)
NO (1) NO984163L (xx)
NZ (1) NZ331736A (xx)
PL (1) PL188888B1 (xx)
TW (1) TW448045B (xx)
WO (1) WO1997033619A1 (xx)
ZA (1) ZA971820B (xx)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130246A0 (en) * 1996-12-11 2000-06-01 Pharmacyclics Inc Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
DE69824853T2 (de) 1997-02-11 2006-01-12 Qlt Inc., Vancouver Zusammensetzung und Gegenstände zur Verminderung der Auswirkung von Entzündungen
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US6117862A (en) 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7097826B2 (en) 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
EP1267935A2 (en) * 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
ATE406914T1 (de) * 2000-02-10 2008-09-15 Massachusetts Eye & Ear Infirm Photodynamische therapie zur behandlung von augenerkrankungen
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
JP2003528926A (ja) * 2000-03-24 2003-09-30 ノバルティス アクチエンゲゼルシャフト 新血管形成の改善された処置
ATE368475T1 (de) 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
EP1357946B1 (en) * 2001-02-06 2008-03-26 QLT Inc. Photodynamic therapy with reduced fluence rate
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (da) 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
US6599891B2 (en) * 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
US20030171320A1 (en) * 2001-11-09 2003-09-11 Guyer David R. Methods for treating ocular neovascular diseases
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2003061696A2 (en) * 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
CA2478250C (en) * 2002-03-20 2011-09-06 Novadaq Technologies Inc. System and method for visualizing fluid flow through vessels
JP2005532393A (ja) * 2002-07-02 2005-10-27 ザ・リージェンツ・オブ・ジ・ユニバーシティ・オブ・カリフォルニア 眼の障害についての処置
ATE535219T1 (de) * 2002-07-17 2011-12-15 Novadaq Technologies Inc Kombinierte photokoagulations- und photodynamische therapie
AU2003299201A1 (en) * 2002-10-03 2004-04-23 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
AU2003301267A1 (en) * 2002-10-18 2004-05-04 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
DK1572748T3 (da) 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
EP1605847B1 (en) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2525447C (en) * 2003-05-14 2013-08-06 Universite De Sherbrooke Amphiphilic trisulfonated porphyrazines for photodynamic applications in medicine
CN100534428C (zh) * 2003-08-25 2009-09-02 上海复旦张江生物医药股份有限公司 血卟啉单甲醚在治疗眼科疾病中的应用
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
JP2007536272A (ja) * 2004-05-07 2007-12-13 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 近視の処置法
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
JP2008510529A (ja) * 2004-08-27 2008-04-10 エレックス メディカル プロプライエタリー リミテッド 選択的眼科レーザ治療
US20090192209A1 (en) * 2004-09-24 2009-07-30 Light Sciences Oncology, Inc. Extended treatment of tumors through vessel occlusion with light activated drugs
ZA200704872B (en) * 2004-11-17 2008-12-31 Mclaurin Joanne Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
JP4937132B2 (ja) 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫原性の低下したｉｌ−７変種
WO2006065727A1 (en) * 2004-12-15 2006-06-22 Light Sciences Corporation Enhanced occlusive effect photodynamic therapy
WO2006091666A2 (en) * 2005-02-23 2006-08-31 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20070122344A1 (en) 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
US20090170957A1 (en) * 2005-10-13 2009-07-02 Antonio Cruz Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
US20070197453A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
CA2644804A1 (en) * 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
WO2007134449A1 (en) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
AU2007308749B2 (en) 2006-10-25 2013-02-14 Alpharet Pty Ltd Retinal regeneration
CA2670405A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and related neurodegenerative diseases
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
WO2008124931A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
EP2656839A1 (en) 2007-04-12 2013-10-30 Waratah Pharmaceuticals, Inc. Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
US20110105626A1 (en) * 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
US8496649B2 (en) * 2007-05-30 2013-07-30 Ellex R&D Pty Ltd Retinal rejuvenation laser
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
WO2009126894A2 (en) * 2008-04-11 2009-10-15 Massachusetts Eye And Ear Infirmary Methods and compositions for the diagnosis and treatment of angiogenic disorders
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
EP2687235A3 (en) 2008-05-02 2014-11-05 Novadaq Technologies Inc. Methods for production and use of substance-loaded erythrocytes (S-LES) for observation and treatment of microvascular hemodynamics
CA2740124A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
KR101018785B1 (ko) * 2008-11-28 2011-03-03 삼성전기주식회사 전자기 밴드갭 구조물 및 회로 기판
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US20140004510A1 (en) 2010-09-24 2014-01-02 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
KR101962991B1 (ko) 2011-08-23 2019-03-27 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안질환 및 질병 치료용 박테리오 클로로필 광민감제
US9211214B2 (en) 2012-03-21 2015-12-15 Valeant Pharmaceuticals International, Inc Photodynamic therapy laser
EP2863801B8 (en) 2012-06-21 2024-06-12 Stryker Corporation Quantification and analysis of angiography and perfusion
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
AU2015327665B2 (en) 2014-09-29 2018-09-27 Stryker European Operations Limited Imaging a target fluorophore in a biological material in the presence of autofluorescence
AU2014408488B2 (en) 2014-10-09 2019-07-18 Stryker European Operations Limited Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
KR20220120711A (ko) 2016-05-26 2022-08-30 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 폐혈관 질환 치료용 조성물 및 방법
WO2018145193A1 (en) 2017-02-10 2018-08-16 Novadaq Technologies ULC Open-field handheld fluorescence imaging systems and methods
KR20190056758A (ko) 2017-11-17 2019-05-27 주식회사 지뉴브 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179120A (en) 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
US5776966A (en) 1992-05-27 1998-07-07 University Of British Columbia Selective cell inactivation in blood
CA2536069C (en) * 1994-03-14 2008-06-03 Massachusetts Eye And Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
JP2961074B2 (ja) 1995-09-06 1999-10-12 明治製菓株式会社 光化学療法用の新生血管閉塞剤

Also Published As

Publication number Publication date
ES2246505T3 (es) 2006-02-16
EP0894009A1 (en) 1999-02-03
CZ299301B6 (cs) 2008-06-11
NZ331736A (en) 2000-06-23
US20120310144A1 (en) 2012-12-06
CN1104908C (zh) 2003-04-09
US6548542B1 (en) 2003-04-15
NO984163L (no) 1998-11-11
US5910510A (en) 1999-06-08
PL328796A1 (en) 1999-02-15
AR004422A1 (es) 1998-12-16
HK1018203A1 (en) 1999-12-17
CZ278998A3 (cs) 1999-05-12
KR19990087682A (ko) 1999-12-27
IL187758A0 (en) 2008-03-20
ATE301473T1 (de) 2005-08-15
PL188888B1 (pl) 2005-05-31
US8239978B2 (en) 2012-08-14
FI981954A0 (fi) 1998-09-11
DE69733943T2 (de) 2006-06-01
JP2006273853A (ja) 2006-10-12
IL220210A0 (en) 2012-07-31
AR042931A2 (es) 2005-07-06
TW448045B (en) 2001-08-01
HUP9902012A2 (hu) 1999-12-28
CA2248087C (en) 2007-10-16
KR100433507B1 (ko) 2004-12-23
CN1213314A (zh) 1999-04-07
CA2248087A1 (en) 1997-09-18
US20030149012A1 (en) 2003-08-07
AU1762697A (en) 1997-10-01
AU705100B2 (en) 1999-05-13
IL126099A (en) 2012-08-30
IL220143A0 (en) 2012-07-31
FI981954L (fi) 1998-11-10
HU227978B1 (en) 2012-07-30
HUP9902012A3 (en) 2000-04-28
JP2000506173A (ja) 2000-05-23
US5756541A (en) 1998-05-26
NO984163D0 (no) 1998-09-10
EP0894009B1 (en) 2005-08-10
US20080058403A1 (en) 2008-03-06
IL126099A0 (en) 1999-05-09
FI981954A7 (fi) 1998-11-10
WO1997033619A1 (en) 1997-09-18
DK0894009T3 (da) 2005-10-31
DE69733943D1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
ZA971820B (en) Improved vision through photodynamic therapy of the eye.
EP0789592A4 (en) GENE EYE THERAPY
ZA987839B (en) Combination therapy.
GB2287652B (en) Efficient photodynamic treatment
ZA987843B (en) Combination therapy.
ZA9711029B (en) Therapeutic agents.
AU129169S (en) Goggles
EP1007028A4 (en) TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE
AU134461S (en) Eyeglasses body including lenses
EP0584919A3 (en) Rhythmic glasses for athletics.
GB2333860B (en) Lightweight safety spectacles
AU136250S (en) Safety spectacles
AU7691698A (en) Examining the optic nerve head blood circulation
GB2292305B (en) Safety goggles
GB2311620B (en) Swimming goggles
GB9609715D0 (en) Goggles
TW469843U (en) Goggles
GB9701111D0 (en) Swimming goggles
TW362513U (en) Goggles
AU5242198A (en) Vision improving eye solution
GB9621203D0 (en) Eye glasses
GB9417515D0 (en) Dye the eye
ZA977136B (en) Ophthalmic composition with prolonged residence time on the eye.
HK1002822B (en) Safety goggles
GB9304371D0 (en) The vision humane spider catcher